We use cookies to create the best experience for you. Keep on browsing if you are OK with that, or find out how to manage cookies.
Nobody downloaded yet

Biosimilar - Research Paper Example

Comments (0)
The Emergence of Biosimilars Abstract Biosimilar drugs offer inexpensive alternatives to medication therapy. However, many factors must be considered regarding the safety of the patient, the efficacy of the biosimilar, and the general impact on society. This article discusses the therapeutic value of biosimilars, the biochemistry of the drugs, and the potential for biosimilars to effectively treat disease…
Download full paper

Extract of sample

Download file to see previous pages... Although it is the hope that their introduction may lower the cost of such expensive medicinal products, there have been concerns over the introduction and manufacturing considerations, immunogenicity, degree of similarity of these complex drugs, and regulatory approaches to biosimilars around the world. In addition, of concern are arguments and techniques employed by pharmaceutical companies to advance or discredit biosimilars, as well as issues with post-marketing surveillance programs and their limitations. The issues associated with introduction of biosimilar medicines across a range of pharmacological indications are controversial, as well as differences between biopharmaceutical products not subjected to regulatory approval and regulatory approved medicines. There are rapid changes in licensing of biosimilars and regulatory approval. Non-transparent promotion of biosimilar products gives clinicians a need to be wary. Hopefully, widespread availability of biopharmaceutical products will be provided by biosimilar medicines (Roger, 2010). ...
The manufacture of a biopharmaceutical involves several isolation and purification steps, and the product is complex. In terms of safety and efficacy of the product, even minor changes in production can have serious implications, and these procedures are proprietary to the manufacturer of the originator product. Existing and future regulation should prevent inappropriate and automatic substitution of a biosimilar for a reference biopharmaceutical product, and biosimilars should not be brought to market using the same procedure applied to generics (Misra A, 2010). Living systems or organisms are used to produce biological products, medicines, and therapeutic agents. Because of their expensive cost, access to these life-saving biological products is limited. In the next few years, patents on the early biological products will soon expire. This will allow other biotech/biopharmaceutical companies to manufacture the generic versions of the biological products, which are referred to as biosimilar medicinal products by the European Medicine Agency of the European Union, or as follow-on biological products by the U.S. Food and Drug Administration. Increase in patients' access to the much-needed biological pharmaceuticals by competition of cost-effective follow-on biological products with equivalent efficacy and safety can cut down the costs. Evaluation of equivalence (similarity) between the biosimilar products and their corresponding innovator product is a great challenge for both the scientific community and regulatory agencies due to the complexity and heterogeneity of the molecular structure, complicated manufacturing process, different analytical methods, and possibility of severe ...Download file to see next pagesRead More
Comments (0)
Click to create a comment
Biopharmaceuticals against Viral disease - development and pharmaceutical action
Approximately one third of the drugs currently in development are biopharmaceuticals (Sekhon, 2010). This paper will examine biopharmaceuticals more in detail followed by
4 Pages(1000 words)Research Paper
Litigating a tax matter--the judicial process
Political figures such as senates overturn rules that limit the legislation that can be imposed on appropriations bills that make it difficult to
7 Pages(1750 words)Essay
Health care reform to address access
Quality and affordable health care is significant in improving access to health care, in the sense that, it calls for immediate improvements in eliminating lifetime and unreasonable annual limits on benefits, offers help to those uninsured because of pre-existing
2 Pages(500 words)Essay
Genentech: After the Acquisition by Roche
The company strongly view that “the success of their venture depended on luring and keeping big-brain bioscience talent.” (Morris, 2006). In that direction, the company currently employs around 12000 employees, which include researchers,
3 Pages(750 words)Essay
In this institution the company has made use of the increasing knowledge regarding the subject of gene families and with this new knowledge they are continuously involved
4 Pages(1000 words)Essay
(MHRA) have been structured with the application being able to contain information-demonstrating biosimilarity on data that is derived from analytical studies showing that the biological product is highly similar to the reference product (Association, 2011). Animal studies that
4 Pages(1000 words)Essay
Globalisation today: what it is and what it means for international marketing 02161
The factors include increased competition, choice of location, increased opportunity and many more. However, few are discussed in the note so as to highlight the important aspects of business. A number of studies have been reviewed, which encompass the concept of
8 Pages(2000 words)Essay
Let us find you another Research Paper on topic Biosimilar for FREE!
Contact us:
Contact Us Now
FREE Mobile Apps:
  • About StudentShare
  • Testimonials
  • FAQ
  • Blog
  • Free Essays
  • New Essays
  • Essays
  • The Newest Essay Topics
  • Index samples by all dates
Join us:
Contact Us